Shares of Brainstorm Cell Therapeutics Inc. (BCLI) are up almost 10% in pre-market trading Tuesday, after the company announced that the FDA has designated NurOwn™ as a Fast Track product for the treatment of amyotrophic lateral sclerosis. According to the company’s press release, NurOwn consists of autologous mesenchymal stem cells that have been induced to secrete neurotrophic factors, and is currently being studied in a randomized, double-blind, placebo-controlled phase 2 clinical trial in ALS patients.
“We are pleased that the FDA has granted Fast Track status for NurOwn as this will allow us greater and more frequent dialogue with the Agency as we continue the development of this ground-breaking cell therapy for the treatment of ALS,” Tony Fiorino, MD, PhD, Chief Executive Officer of BrainStorm said in a statement. “We expect Fast Track designation, which recognizes the potential of NurOwn as to address an unmet medical need in ALS, to help speed and improve our development program.”
BCLI currently prints a one year return of about 29.00% and a year-to-date return of around 43.33%.
The chart below shows where the equity has traded over the last 52 weeks, with the 50-day and 200-day MAs included.
AGCO Corporation (AGCO) shares tumbled 9.26% in in pre-market trading Tuesday after the company announced that it has updated its outlook for net income per share for the third quarter and full year of 2014. AGCO now expects Q3 net income per share to be in a range from $0.60 to $0.65, while full year 2014 net income per share is expected to range from $4.10 to $4.30. AGCO cited lower sales levels across all regions, lower production and FX headwind as some of the reasons for the revised estimates.
Following the company’s Q3 EPS below consensus guidance, Bank of America (BAC) downgraded the name to ‘Neutral’ from ‘Buy’.
On valuation-measures, shares of AGCO Corporation have a trailing-12 and forward P/E of 8.63 and 10.66, respectively. P/E to growth ratio is 1.01, while t-12 profit margin is 5.12%. EPS registers at $5.46. The company has a market cap of $4.42B and a median Wall Street price target of $54.00 with a high target of $72.00.
On trading-measure, AGCO has a beta of 1.99 and a short float of 11.50%. In the past 52 weeks, shares of Duluth, Georgia-based farm equipment maker have traded between a low of $45.00 and a high of $64.60 with the 50-day MA and 200-day MA located at $47.27 and $52.27 levels, respectively.
AGCO currently prints a one year loss of about 23.60% and a year-to-date loss of around 20.10%.
Shares of Sodastream International Ltd (SODA) are trading down more than 16% to $22.85 in Tuesday’s pre-market session after the company said Q3 revs will come in at approximately $125 million, below Street estimates of $154 million.
“We are very disappointed in our recent performance,” Daniel Birnbaum, CEO of SodaStream said in a statement. “Our U.S. business underperformed due to lower than expected demand for our soda makers and flavors which was the primary driver of the overall shortfall in the third quarter.”
On valuation-measures, shares of SodaStream Int’l have a trailing-12 and forward P/E of 20.98 and 13.19, respectively. P/E to growth ratio is 0.59, while t-12 profit margin is 4.91%. EPS registers at $1.31. The company has a market cap of $577.81M and a median Wall Street price target of $39.00 with a high target of $48.00.
On trading-measure, SODA has a beta of 1.13 and a short float of 32.17%. In the past 52 weeks, shares of the producer of soda-making systems have traded between a low of $27.44 and a high of $64.00 with the 50-day MA and 200-day MA located at $31.92 and $35.71 levels, respectively.
SODA currently prints a one year loss of about 58.50% and a year-to-date loss of around 45%.
Las Vegas Sands (LVS) shares are down 2.90% to $61.10 on Tuesday’s pre-market session after the name was downgraded by Deutsche Bank (DB) to ‘Hold’ with a $65 price target. DB said the company’s competitive advantages are easing.
Las Vegas Sands Corp., currently valued at $50.78B, has a median Wall Street price target of $82.50 with a high target of $95.00. Approximately 5,982,159 shares have already changed hands, compared to the stock’s average daily volume of 5,656,890.
In the past 52 weeks, shares of the clinical-stage biopharmaceutical company have traded between a low of $59.08 and a high of $88.28 with the 50-day MA and 200-day MA located at $63.98 and $72.40 levels, respectively. Additionally, shares of LVS trade at a P/E ratio of 1.02 and have a Relative Strength Index (RSI) and MACD indicator of 51.40 and +0.64, respectively.
LVS currently prints a one year loss of about 2.75% and a year-to-date loss of around 18.55%.